Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
367
datasets available to search
ShareScore release 0.9.0
Dataset results
367 results for “Ibrutinib”
ibrutinib resistance mantle cell lymphoma [Pt_RNA]
GEO Series GSE141335. Homo sapiens. 60 samples. Type: Expression profiling by high throughput sequencing.
Targeting DNMT3A-mediated oxidative phosphorylation to overcome ibrutinib resistance in mantle cell lymphoma
GEO Series GSE227976. Homo sapiens. 11 samples. Type: Expression profiling by high throughput sequencing; Genome binding/occupancy profiling by high throughput sequencing.
Chromatin mapping and single-cell immune profiling defines the temporal dynamics of ibrutinib drug response in chronic lymphocytic leukemia [ATAC-seq]
GEO Series GSE111013. Homo sapiens. 176 samples. Type: Genome binding/occupancy profiling by high throughput sequencing.
Gene expression data of parental and ibrutinib-resistant TMD8 cells.
GEO Series GSE93985. Homo sapiens. 4 samples. Type: Expression profiling by array.
Chromatin mapping and single-cell immune profiling defines the temporal dynamics of ibrutinib drug response in chronic lymphocytic leukemia
GEO Series GSE111015. Homo sapiens. 188 samples. Type: Genome binding/occupancy profiling by high throughput sequencing; Expression profiling by high throughput sequencing.
Synergistic activity of BET protein antagonist-based combinations in Mantle Cell Lymphoma cells sensitive or resistant to ibrutinib
GEO Series GSE70651. Homo sapiens. 6 samples. Type: Expression profiling by array.
Ipilimumab, Ibrutinib, and Nivolumab for the Treatment of Chronic Lymphocytic Leukemia and Richter Transformation
ClinicalTrials.gov study NCT04781855. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Ibrutinib Plus Rituximab and Lenalidomide in Treating Elderly Participants With Newly Diagnosed Mantle Cell Lymphoma
ClinicalTrials.gov study NCT03232307. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Ibrutinib Adapted to Response in Patients With CLL
ClinicalTrials.gov study NCT05360758. IPD Sharing: YES. Countries: 0. Publications: 0.
Outcomes of Unfit Patients With CLL Included in the GIMEMA LLC1114 Trial Who Discontinued Ibrutinib Due to Reasons Other Than Disease Progression
ClinicalTrials.gov study NCT06084923. IPD Sharing: NO. Countries: 0. Publications: 0.
Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Duvortuxizumab (JNJ-64052781) Plus Ibrutinib in Lymphoma
ClinicalTrials.gov study NCT02743546. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Ibrutinib Combined With Rituximab for Treatment of Relapsed Refractory MYD88 and CD79A/B (or CD79B Alone) DLBCL Who Have Received at Least Two Prior Therapies
ClinicalTrials.gov study NCT04994626. IPD Sharing: NO. Countries: 0. Publications: 0.
Obinutuzumab With High-dose Ibrutinib for the Treatment of Patients With Chronic Lymphocytic Leukemia With Progressive Disease on Single Agent Ibrutinib.
ClinicalTrials.gov study NCT02611908. IPD Sharing: Not stated. Countries: 0. Publications: 0.
An Open Label Treatment Use Protocol for Ibrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma
ClinicalTrials.gov study NCT01833039. IPD Sharing: Not stated. Countries: 3. Publications: 0.
Combination of Ibrutinib and As2O3 in the Treatment of CLL
ClinicalTrials.gov study NCT02757040. IPD Sharing: UNDECIDED. Countries: 0. Publications: 0.
Ibrutinib and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia After Ibrutinib Resistance
ClinicalTrials.gov study NCT03943342. IPD Sharing: NO. Countries: 0. Publications: 0.
Early Access Program (EAP) for Ibrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
ClinicalTrials.gov study NCT02437019. IPD Sharing: Not stated. Countries: 1. Publications: 0.
A Study of Acalabrutinib in Combination With Rituximab Versus Ibrutinib Versus Acalabrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma
ClinicalTrials.gov study NCT02735876. IPD Sharing: UNDECIDED. Countries: 0. Publications: 0.
Study of Ibrutinib Followed by Ibrutinib in Combination With Nivolumab in Non-Small Cell Lung Cancer (NSCLC)
ClinicalTrials.gov study NCT02950038. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Ibrutinib With or Without Bortezomib and Dexamethasone in Treating Patients With Relapsed or Refractory Immunoglobulin Light Chain Amyloidosis
ClinicalTrials.gov study NCT03130348. IPD Sharing: Not stated. Countries: 0. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.